Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
Abstract Background The Coronavirus disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a pandemic, affecting the therapeutic Sanitizers/Disinfectants management for Multiple Sclerosis (MS).Any decision regarding the discontinuation of high-potency agents for moderate and highly active M